At a Glance
- Company: Anthropic (Claude AI maker); Coefficient Bio (stealth startup)
- Location: San Francisco (Anthropic); New York (Coefficient)
- Deal value: $400M all-stock transaction (~0.1% dilution to Anthropic’s $380B valuation)
- Focus area: AI for drug discovery, biological research workflows
- Next steps: Team joins Anthropic’s healthcare/life sciences group
What happened?
Anthropic has acquired Coefficient Bio, a stealth AI biotech startup founded less than a year ago, in an all-stock deal valued at approximately $400 million. The acquisition brings a team of fewer than 10 ex-Genentech computational biologists into Anthropic’s healthcare and life sciences division.
Why does it matter?
Anthropic, valued at $380B after its February Series G, is pivoting from general-purpose AI to industry-specific infrastructure, targeting drug discovery’s $16B+ market (10% CAGR to 2034). Coefficient’s physics-based simulations and protein design expertise could build biology-specific foundation models, accelerating from AI tools to core R&D rails.
Who’s behind it?
Coefficient Bio was founded in mid-2025 by Samuel Stanton (CEO, ex-Genentech Prescient Design), Nathan Frey (CTO, ex-Biogen principal scientist) and Joyce Hong (ex-Roivant principal). Backed by Dimension VC (50% stake), the team specialised in AI for molecular behaviour modelling and compound optimisation.
How was it achieved?
The deal secures talent for Anthropic’s Claude for Life Sciences tools, enabling end-to-end drug workflows from target ID to clinical strategy. Low dilution (~0.1%) reflects high conviction in AI’s biotech transformation, despite 95% AI pilot failure rates.
What’s next?
Coefficient’s team will develop production-ready AI biology systems within Anthropic’s health division. Expect new models for protein folding, binding and toxicity prediction, with potential pharma partnerships. Success could redefine AI’s biotech role beyond benchmarks.
What are people saying?
Anthropic (via reporting): Infrastructure bet on AI drug discovery S-curve. Analysts: High-conviction talent grab; execution key amid integration risks.